Geron Corporation (GERN) Soars 6.12% on February 19

Geron Corporation (GERN) Soars 6.12% on February 19

Geron Corporation (GERN) had a good day on the market for Tuesday February 19 as shares jumped 6.12% to close at $1.56. About 5.07 million shares traded hands on 11,174 trades for the day, compared with an average daily volume of n/a shares out of a total float of 186.35 million. After opening the trading day at $1.48, shares of Geron Corporation stayed within a range of $1.59 to $1.42.

With today’s gains, Geron Corporation now has a market cap of $290.7 million. Shares of Geron Corporation have been trading within a range of $6.99 and $0.95 over the last year, and it had a 50-day SMA of $n/a and a 200-day SMA of $n/a.

Geron Corp is a clinical stage biopharmaceutical company. Its focus is the development of a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. Imelstat is expected to directly obstruct malignant-cell proliferation. The company has an exclusive collaboration and license agreement with Janssen Biotech to develop and commercialize imetelstat worldwide for oncology and other human therapeutic uses.

Geron Corporation is based out of Menlo Park, CA and has some 18 employees. Its CEO is .

error: Content is protected !!